FY2025 EPS Estimates for Savara Boosted by Lifesci Capital

Savara Inc. (NASDAQ:SVRA) – Research analysts at Lifesci Capital increased their FY2025 EPS estimates for Savara in a note issued to investors on Thursday, November 13th. Lifesci Capital analyst F. Brisebois now anticipates that the company will earn ($0.53) per share for the year, up from their prior forecast of ($0.55). Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.45) per share. Lifesci Capital also issued estimates for Savara’s Q4 2025 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.49) EPS.

SVRA has been the subject of several other research reports. JMP Securities raised their price objective on Savara from $8.00 to $11.00 and gave the company a “market outperform” rating in a research report on Thursday, October 23rd. HC Wainwright lifted their price target on shares of Savara from $5.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, September 3rd. Wall Street Zen raised shares of Savara from a “sell” rating to a “hold” rating in a research note on Saturday. Citigroup reaffirmed an “outperform” rating on shares of Savara in a research note on Thursday, October 23rd. Finally, Oppenheimer lifted their target price on shares of Savara from $8.00 to $9.00 and gave the company an “outperform” rating in a report on Friday, November 14th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $8.29.

Savara Trading Down 0.7%

NASDAQ SVRA opened at $4.17 on Monday. The firm has a market capitalization of $848.46 million, a PE ratio of -8.34 and a beta of 0.45. The stock’s 50 day moving average is $3.82 and its 200 day moving average is $3.07. Savara has a twelve month low of $1.89 and a twelve month high of $4.51. The company has a quick ratio of 11.08, a current ratio of 11.08 and a debt-to-equity ratio of 0.25.

Savara (NASDAQ:SVRA) last posted its earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01).

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Russell Investments Group Ltd. lifted its stake in shares of Savara by 930.5% in the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after buying an additional 9,463 shares in the last quarter. Prudential Financial Inc. bought a new position in Savara in the 2nd quarter valued at approximately $30,000. BNP Paribas Financial Markets boosted its stake in Savara by 52.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock valued at $31,000 after purchasing an additional 4,626 shares during the last quarter. May Hill Capital LLC bought a new stake in shares of Savara in the 2nd quarter worth $32,000. Finally, Brevan Howard Capital Management LP bought a new stake in shares of Savara in the 2nd quarter worth $33,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.